Carroll has been promoted from his position as vice president at Lilly Ventures to senior vice president.

Roche co-led a round for AveXis that will help fund development of its spinal muscular atrophy treatment.

Orphazyme has secured $24m in a Novo-backed round that will fund a clinical trial for its lead drug candidate, a treatment for a rare cholesterol-caused disease.

New investors including Hearst Health Ventures and Catholic Health Initiatives have joined the company's series D round, taking its overall funding to almost $83m.

The Genomic Health-backed genetic testing company intends to raise $86m from an initial public offering on the New York Stock Exchange.

Healthcare provider Allscripts participated in Par8o's series A round together with Indiana University Health, Atlas Venture and Founder Collective.

Retrosense Therapeutics, which is working on a treatment for vision loss, has raised $6m from investors including medical diagnostics company Nerveda.

Cancer immunotherapy company Surface Oncology's $35m Eli Lilly, Amgen and Novartis-backed series A round demonstrates the recent success of oncology companies in the venture capital market.

Healthcare provider Allscripts participated in Par8o's series A round together with Indiana University Health, Atlas Venture and Founder Collective.